ASNS - Arsanis, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
12.22
-1.75 (-12.53%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close13.97
Open13.52
Bid0.00 x 0
Ask0.00 x 0
Day's Range12.21 - 13.72
52 Week Range12.21 - 25.04
Volume125,281
Avg. Volume72,723
Market Cap174.678M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-54.58
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Business Wire21 days ago

    Arsanis Announces Closing of Initial Public Offering

    Arsanis, Inc. , a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced the closing of its initial public offering of 4,600,000 shares of its common stock at a public offering price of $10.00 per share, including 600,000 additional shares of common stock issued upon the exercise in full by the underwriters ...

  • MarketWatch26 days ago

    Biotech Arsanis prices IPO at $10, below $15 to $17 price range

    Arsanis Inc. priced its initial public offering at $10 late Wednesday, well below its $15 to $17 price range. The clinical-stage biotech sold 4 million shares to raise $40 million. Underwriters have the ...

  • GlobeNewswire26 days ago

    Arsanis Announces Pricing of Initial Public Offering

    WALTHAM, Mass. and VIENNA, Austria, Nov. 15, 2017-- Arsanis, Inc., a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, ...